Trial · NCT02542696
Outcomes19
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase | up to approximately 3 years | Based on Long Term Safety Full Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | The Percentage of Instances Where a Full ON Response Was Achieved Within 30 Minutes After Self-administration of Study Medication at Week 24 Visit (LTS V4) of the LTS Phase Based on the Home Dosing Diary Entries. | Week 24 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percentage of instances | MEAN |
| SECONDARY | The Percentage of Instances Where a Full ON Response Was Achieved Within 30 Minutes After Self-administration of Study Medication at Week 36 Visit (LTS V5) of the LTS Phase Based on the Home Dosing Diary Entries. | Week 36 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percentage of instances | MEAN |
| SECONDARY | The Percentage of Instances Where a Full ON Response Was Achieved Within 30 Minutes After Self-administration of Study Medication at Week 48 Visit (LTS V6) of the LTS Phase Based on the Home Dosing Diary Entries. | Week 48 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percentage of instances | MEAN |
| SECONDARY | Percentage of Subjects With a Subject-rated Full ON Response Within 30 Minutes at Week 24 Visit (LTS V4) of the LTS Phase. | Week 24 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percent of participants | NUMBER |
| SECONDARY | Percentage of Subjects With a Subject-rated Full ON Response Within 30 Minutes at Week 36 Visit (LTS V5) of the LTS Phase. | Week 36 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percent of participants | NUMBER |
| SECONDARY | Percentage of Subjects With a Subject-rated Full ON Response Within 30 Minutes at Week 48 Visit (LTS V6) of the LTS Phase. | Week 48 | Based on the number of subjects who provided data at the specified timepoint in the analysis population | percent of participants | NUMBER |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 15 Minutes After Dosing at Week 24 Visit (LTS V4) of the LTS Phase. | Week 24, 15 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 30 Minutes After Dosing at Week 24 Visit (LTS V4) of the LTS Phase. | Week 24, 30 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 60 Minutes After Dosing at Week 24 Visit (LTS V4) of the LTS Phase. | Week 24, 60 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 90 Minutes After Dosing at Week 24 Visit (LTS V4) of the LTS Phase. | Week 24, 90 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 15 Minutes After Dosing at Week 36 Visit (LTS V5) of the LTS Phase. | Week 36, 15 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 30 Minutes After Dosing at Week 36 Visit (LTS V5) of the LTS Phase. | Week 36, 30 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 60 Minutes After Dosing at Week 36 Visit (LTS V5) of the LTS Phase. | Week 36, 60 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 90 Minutes After Dosing at Week 36 Visit (LTS V5) of the LTS Phase. | Week 36, 90 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 15 Minutes After Dosing at Week 48 Visit (LTS V6) of the LTS Phase. | Week 48, 15 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 30 Minutes After Dosing at Week 48 Visit (LTS V6) of the LTS Phase. | Week 48, 30 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 60 Minutes After Dosing at Week 48 Visit (LTS V6) of the LTS Phase. | Week 48, 60 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
| SECONDARY | Mean Change From Pre-dose in MDS-UPDRS Part III Motor Examination (MDS UPDRS MOTOR) Score at 90 Minutes After Dosing at Week 48 Visit (LTS V6) of the LTS Phase. | Week 48, 90 mins after dosing | Based on the number of subjects who provided data at the specified timepoint in the analysis population | Units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02542696/outcomes